HUTCHMED (China) Limited develops and commercializes targeted therapies and immunotherapies for cancer and immunological diseases through a China-based commercial organization and a global clinical pipeline. News for HCM centers on marketed oncology products such as FRUZAQLA and ELUNATE for fruquintinib, ORPATHYS for savolitinib, China regulatory actions, and partner-driven commercialization outside China.
Recurring updates also cover pipeline compounds including sovleplenib, HMPL-760 and HMPL-A580, clinical data presented at oncology meetings, and the company’s Antibody-Targeted Therapy Conjugate platform. Corporate items include annual results, product-license updates such as TAZVERIK in China, board and committee changes, and disclosures tied to HUTCHMED’s Nasdaq, AIM and HKEX listings and ADR structure.
HUTCHMED (HCM) has received US FDA Orphan Drug Designation for sovleplenib to treat autoimmune hemolytic anemia, a disorder that destroys red blood cells. This is sovleplenib’s second US orphan designation, following one for primary immune thrombocytopenia, a platelet disorder, announced in October 2026.
The designation provides eligibility for development incentives, including qualified clinical-trial tax credits, user fee waivers and specialized FDA guidance. Seven years of US market exclusivity is available upon FDA approval for the designated indication. In China, applications for sovleplenib in primary immune thrombocytopenia and warm autoimmune hemolytic anemia remain under regulatory review. HUTCHMED describes the supporting pivotal ESLIM-01 and ESLIM-02 trial data, respectively, as positive. The company retains all worldwide rights to sovleplenib.
HUTCHMED (HCM) announced acceptance for review in Europe and Japan of regulatory filings for ORPATHYS plus TAGRISSO in lung cancer. AstraZeneca submitted the applications for patients with MET overexpression or amplification whose disease progressed after EGFR-targeted therapy. A US application was submitted in September 2026.
The supporting SAFFRON Phase III trial compared the combination with platinum-based chemotherapy after progression on TAGRISSO. Median progression-free survival, the time without disease worsening or death, was 7.6 versus 5.4 months; median overall survival was 17.8 versus 12.9 months. Both improvements were statistically significant. No new safety concerns emerged. The European and Japanese applications remain under review.
HUTCHMED (HCM) has received US FDA Orphan Drug Designation for sovleplenib to treat primary immune thrombocytopenia, an autoimmune disorder that increases bleeding risk. Sovleplenib is an oral inhibitor of spleen tyrosine kinase, an enzyme involved in immune signaling.
The designation provides access to development incentives, including qualified clinical-trial tax credits, user fee waivers and specialized FDA guidance. If FDA-approved for the designated indication, sovleplenib would be eligible for 7 years of US market exclusivity. In China, applications for primary immune thrombocytopenia and warm antibody autoimmune hemolytic anemia remain under regulatory review, supported by positive pivotal ESLIM-01 and ESLIM-02 trial data, respectively. HUTCHMED retains all worldwide rights to sovleplenib.
HUTCHMED (HCM) will co-host an expert webcast with Citigroup on November 5, 2026, discussing recent Phase III savolitinib data in lung cancer.
The analyst and investor event will cover MET-driven non-small cell lung cancer data presented at ESMO Congress 2026. SANOVO principal investigator Professor Yi-Long Wu will lead the discussion, with HUTCHMED’s Dr Weiguo Su joining to discuss development progress and the global regulatory outlook using SANOVO and SAFFRON data. The webcast starts at 4:30 pm HKT / 8:30 am GMT / 3:30 am EST, in Chinese (Putonghua) with simultaneous English interpretation.
HUTCHMED (HCM) reported Phase III SANOVO results showing ORPATHYS plus TAGRISSO reduced progression or death risk by 44% versus TAGRISSO alone.
The China trial enrolled 326 previously untreated patients with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer and MET overexpression. Median progression-free survival, the time before disease worsens or death, was 24.9 versus 13.8 months overall. In the high-MET group, it was 24.8 versus 11.1 months, with a 55% risk reduction. Both comparisons were statistically significant. Median overall survival, a secondary endpoint, was 44.5 versus 34.9 months overall.
Adverse events caused treatment discontinuation in 14.8% of combination recipients; fatal adverse events excluding disease progression were 4.3% versus 4.8%. HUTCHMED reported no new safety concerns and plans a supplemental New Drug Application in China for first-line use.
HUTCHMED (HCM) reported that ORPATHYS plus TAGRISSO improved survival versus chemotherapy in the global Phase III SAFFRON lung cancer trial.
The 338-patient trial enrolled patients with EGFR-mutated non-small cell lung cancer, high MET protein levels or gene amplification, and progression after TAGRISSO. Median progression-free survival, the time without disease worsening or death, was 7.6 versus 5.4 months; the risk fell 45%. Median overall survival was 17.8 versus 12.9 months, with a 32% reduction in death risk. Both improvements were statistically significant. Grade 3 or higher adverse events from all causes occurred in 64% versus 63% of patients.
A US application has been submitted, and submissions in Europe and Japan are progressing as planned. Results were presented at ESMO Congress 2026 and simultaneously published in The New England Journal of Medicine.
HUTCHMED (HCM) closed an exclusive agreement granting a GSK subsidiary rights to develop and commercialize its cancer drug candidate HMPL-A830. The territory excludes Mainland China, Hong Kong, Macau and Taiwan. Closing followed completion of customary conditions, including antitrust regulatory reviews.
HUTCHMED expects to receive US$110 million upfront shortly and may receive additional development, regulatory and commercial milestones totaling up to US$1.185 billion, plus tiered royalties on annual net sales. HMPL-A830 combines a KRAS inhibitor with an antibody targeting EGFR, two proteins involved in cancer signaling. Its Phase Ia trial began in China and the US in September 2026 for patients with unresectable, advanced or metastatic solid tumors. HUTCHMED is responsible for global Phase I development; the GSK subsidiary handles subsequent clinical development and commercialization in its territory.
HUTCHMED (HCM) announced AstraZeneca's US application for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutated lung cancer.
The application seeks approval for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have MET overexpression or amplification and whose disease progressed on or after EGFR-targeted therapy. In the 338-patient Phase III SAFFRON trial, the combination improved progression-free and overall survival versus doublet platinum-based chemotherapy among patients whose disease progressed on TAGRISSO. Both improvements were statistically significant. The safety profile matched the medicines' known profiles, with no new concerns. US approval remains pending.
HUTCHMED (HCM) has initiated a global Phase Ia trial of HMPL-A830 in patients with advanced solid tumors. The first patient received a dose in China on September 24, 2026. The first-in-human, multicenter study is enrolling patients with unresectable, advanced or metastatic solid tumors. HMPL-A830 combines a KRAS inhibitor with an antibody targeting EGFR, a protein involved in tumor growth. Phase Ia will assess safety and tolerability while determining the maximum tolerated dose and a recommended dose for expansion.
A later dose-expansion and optimization stage is intended to examine safety and preliminary anti-tumor activity in selected solid tumors. Under an exclusive agreement signed September 3, 2026, HUTCHMED's subsidiary agreed to grant a GSK subsidiary development and commercialization rights outside Mainland China, Hong Kong, Macau and Taiwan. HUTCHMED's subsidiary is responsible for the global Phase I program.
HUTCHMED (HCM) will feature results from two Phase III savolitinib–osimertinib lung cancer studies at ESMO Congress 2026.
SAFFRON studied patients with EGFR-mutated non-small cell lung cancer (NSCLC) and MET overexpression or amplification after disease progression on osimertinib. High-level results reported August 17 showed statistically significant and clinically meaningful improvements in progression-free and overall survival versus doublet platinum-based chemotherapy. SANOVO studied previously untreated patients in China with locally advanced or metastatic NSCLC, activating EGFR mutations and MET overexpression. High-level results reported August 31 showed a statistically significant and clinically meaningful progression-free survival improvement and a clinically meaningful overall survival benefit versus osimertinib alone.
SAFFRON is scheduled for a Presidential Symposium oral presentation on October 25, and SANOVO for a Proffered Paper oral presentation on October 26. The Madrid congress runs October 23–27.